Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Development of a highly stable and targetable nanoliposomal formulation of topotecan.

Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB.

J Control Release. 2010 Jan 4;141(1):13-21. doi: 10.1016/j.jconrel.2009.08.006. Epub 2009 Aug 15.

PMID:
19686789
2.

Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G.

Clin Cancer Res. 1999 Apr;5(4):909-16.

3.

Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation.

Liu JJ, Hong RL, Cheng WF, Hong K, Chang FH, Tseng YL.

Anticancer Drugs. 2002 Aug;13(7):709-17.

PMID:
12187327
4.

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.

Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC.

Cancer Chemother Pharmacol. 2009 Sep;64(4):741-51. doi: 10.1007/s00280-008-0923-3. Epub 2009 Jan 30.

5.

Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.

Zucker D, Andriyanov AV, Steiner A, Raviv U, Barenholz Y.

J Control Release. 2012 Jun 10;160(2):281-9. doi: 10.1016/j.jconrel.2011.10.003. Epub 2011 Oct 12.

PMID:
22019556
6.

Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.

Zucker D, Barenholz Y.

J Control Release. 2010 Sep 15;146(3):326-33. doi: 10.1016/j.jconrel.2010.05.024. Epub 2010 May 25.

PMID:
20685223
7.

Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.

Patankar NA, Waterhouse D, Strutt D, Anantha M, Bally MB.

Invest New Drugs. 2013 Feb;31(1):46-58. doi: 10.1007/s10637-012-9832-8. Epub 2012 May 22.

PMID:
22615060
8.

In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.

Hao YL, Deng YJ, Chen Y, Wang KZ, Hao AJ, Zhang Y.

J Pharm Pharmacol. 2005 Oct;57(10):1279-87.

PMID:
16259756
9.

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB.

Cancer Res. 2006 Mar 15;66(6):3271-7.

10.

The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.

Dadashzadeh S, Vali AM, Rezaie M.

Int J Pharm. 2008 Apr 2;353(1-2):251-9. doi: 10.1016/j.ijpharm.2007.11.030. Epub 2007 Nov 23.

PMID:
18191511
11.

Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD.

Neuro Oncol. 2011 Dec;13(12):1288-95. doi: 10.1093/neuonc/nor139. Epub 2011 Sep 27.

12.

Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.

Li X, Lu WL, Liang GW, Ruan GR, Hong HY, Long C, Zhang YT, Liu Y, Wang JC, Zhang X, Zhang Q.

Eur J Clin Invest. 2006 Jun;36(6):409-18.

PMID:
16684125
13.

Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.

Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK, Kim DD.

Pharm Res. 2007 Dec;24(12):2402-11. Epub 2007 Sep 9.

PMID:
17828616
14.

In vitro and in vivo studies of different liposomes containing topotecan.

Hao YL, Deng YJ, Chen Y, Wang XM, Zhong HJ, Suo XB.

Arch Pharm Res. 2005 May;28(5):626-35.

PMID:
15974453
15.

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.

Mol Cancer Ther. 2001 Dec;1(2):85-94.

16.

The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.

Fugit KD, Anderson BD.

J Control Release. 2014 Jan 28;174:88-97. doi: 10.1016/j.jconrel.2013.11.003. Epub 2013 Nov 12.

17.

Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.

Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD.

Cancer Res. 2000 Jul 1;60(13):3389-93.

18.

Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator?

Cui J, Li C, Wang C, Li Y, Zhang L, Zhang L, Xiu X, Li Y, Wei N.

Int J Pharm. 2010 Oct 31;399(1-2):31-6. doi: 10.1016/j.ijpharm.2010.07.050. Epub 2010 Aug 1.

PMID:
20678563
19.

Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo.

Nie T, Wong CC, Alston N, Aro P, Constantinides PP, Rigas B.

Br J Pharmacol. 2012 Jun;166(3):991-1001. doi: 10.1111/j.1476-5381.2011.01799.x.

20.

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.

Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C.

Oncology. 1999;56(1):1-12. Review.

PMID:
9885371

Supplemental Content

Support Center